p16 and p53 expression levels are used as differential immunostaining markers to distinguish high-grade serous carcinoma from other histological types of ovarian carcinoma and SC from other histological types of endometrial carcinoma. This evidence concerns the gene CDKN2A and serous adenocarcinoma.